Premium
P4‐002: The first third‐generation Alzheimer mouse, PLB1: Motor performance and anxiety assessment
Author(s) -
Utan Aneli,
Melis Valeria,
Platt Bettina,
Riedel Gernot
Publication year - 2009
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2009.04.872
Subject(s) - anxiety , balance (ability) , elevated plus maze , genetically modified mouse , psychology , motor coordination , motor learning , audiology , neuroscience , transgene , medicine , developmental psychology , chemistry , psychiatry , biochemistry , gene
Background: Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder with a devastating prognosis. As previously reported, passive immunization using monoclonal antibodies against Abeta (Aß) was successful in improving cognitive deficits in transgenic mice models of AD. The detection of antibodies against Aß in human immunoglobulin (hIVIg) offers an alternative approach of passive immunization using natural occurring polyclonal anti Aß antibodies. The present study was arranged to test if acute treatment with hIVIg has a therapeutic effect on cognition in 9-10 months old Tg2576 mice. Methods: Tg2576 mice (9-10 months of age) were treated acutely with either hIVIg (400 mg, i.p.) or vehicle 1 day before assessing spatial and non-spatial memory using the object recognition test and the novel object location task. Results: Our data revealed no significant difference between hIVIg and control Tg2576 mice in the object recognition task. Both immunized and control group showed increased interaction time with the novel object versus the sample object. However, in contrast to the novel object recognition test, our results of the novel object location task showed a significant trend towards an improvement of spatial memory in immunized Tg2576 mice, indicated by an increase in interaction time with objects moved to a novel location. Conclusions: Acute passive immunization with hIVIg can reverse spatial memory deficits in Tg2576 mice using the object location memory task, therefore showing a therapeutic effect. These findings lead to the conclusion that acute passive immunization with hIVIg might be a promising approach for the treatment of AD.